8/20/2019 8:03:10 AM
Eiger Announces FDA Breakthrough Therapy Designation For Peginterferon Lambda For HDV Infection
6/18/2019 10:22:33 AM
Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $35 Price Target
5/9/2019 4:06:20 PM
Eiger BioPharma Q1 Loss/share $0.90 Vs. Loss $0.84 Year Ago
4/17/2019 11:22:40 PM
Eiger BioPharmaceuticals Prices Public Offering Of 4.50 Mln Shares At $11.00/shr
4/17/2019 4:02:43 PM
Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
3/28/2019 7:21:51 AM
Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $43 Price Target
3/14/2019 4:12:53 PM
Eiger BioPharmaceuticals Q4 Loss/share $0.92 Vs. Loss $1.11 Year Ago
3/13/2019 8:04:52 AM
Eiger Reports Late-Breaker Oral Presentation Of Peginterferon Lambda Phase 2 LIMT Study At Int'l Liver Congress 2019
2/6/2019 8:09:18 AM
Eiger BioPharma Says Patent Protection For Lonafarnib Boosted With Ritonavir For HDV Infection In Europe And Japan
2/4/2019 8:14:31 AM
Eiger Says An Oral Presentation Granted For Results Of Phase 2 PREVENT Study At ENDO 2019
12/19/2018 8:09:02 AM
Eiger Says Breakthrough Therapy Designation Granted By FDA For Lonafarnib
12/18/2018 8:22:17 AM
Eiger Announces PRIME Designation Granted By EMA For Lonafarnib For Hepatitis Delta Virus Infection
12/17/2018 8:18:59 AM
Eiger Reports Breakthrough Therapy Designation Granted By FDA For Lonafarnib For Treatment Of HDV Infection
12/3/2018 4:08:07 PM
Eiger BioPharmaceuticals Appoints Sri Ryali As CFO
12/3/2018 8:12:36 AM
Eiger Reports FDA Acceptance Of IND Application For Lonafarnib For Treatment Of Progeria And Progeroid Laminopathies
11/9/2018 8:07:01 AM
Eiger BioPharmaceuticals Q3 Net Loss $17.1 Mln Or $1.20/Shr Vs Net Loss $9.2 Mln Or $1.10/Shr Last Year
10/23/2018 9:16:28 AM
Eiger Prices Public Offering Of 4.2 Mln Shares At $10.35/Shr
10/22/2018 4:12:39 PM
Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock